Tyrosine kinase receptors

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Lung cancer, Tyrosine kinase receptors, Cancer treatments, Non-small-cell lung carcinoma, Clinical medicine, Brain metastasis, HER2/neu, Cancer, Medicine

These data from Cohorts 1, 2 and 3 of the ongoing ZENITH20 clinical trial assessed the results from 36 patients with brain metastases at baseline with three patients (8%) achieving intracranial complete responses.

Key Points: 
  • These data from Cohorts 1, 2 and 3 of the ongoing ZENITH20 clinical trial assessed the results from 36 patients with brain metastases at baseline with three patients (8%) achieving intracranial complete responses.
  • The presentation titled CNS activity of poziotinib in NSCLC with exon 20 insertion mutations is available on the website for the 2021 ASCO Annual Meeting being held June 4-8, 2021.
  • CNS metastases are a common and life-threatening complication of metastatic disease in NSCLC patients, said Francois Lebel, M.D., Chief Medical Officer of Spectrum Pharmaceuticals.
  • These data show clinically meaningful CNS activity for poziotinib treated NSCLC patients with CNS metastases with EGFR or HER2 exon 20 insertion mutations.

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Organic compounds, Chemical compounds, Aromatic compounds, Lung cancer, Chloroarenes, Quinazolines, Aromatic amines, Tyrosine kinase receptors, Neratinib, Tyrosine kinase inhibitor, Epidermal growth factor receptor, Non-small-cell lung carcinoma

The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that includes a cohort evaluating the safety and efficacy of neratinib administered daily to patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC).

Key Points: 
  • The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study that includes a cohort evaluating the safety and efficacy of neratinib administered daily to patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC).
  • A cohort of 11 patients with EGFR exon 18-mutant NSCLC from the Phase II SUMMIT basket trial, including patients with central nervous system involvement, were evaluated for safety and efficacy.
  • Prior lines of therapies included EGFR tyrosine kinase inhibitors (TKIs) (91%), chemotherapy (55%) and checkpoint inhibitors (IOs) (27%).
  • These results suggest that neratinib can be a potential treatment option for patients with NSCLC and hard-to-treat CNS metastases.

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

Retrieved on: 
Friday, June 4, 2021
Lung cancer, Tyrosine kinase receptors, Epidermal growth factor receptor, Oncogenes, Non-small-cell lung carcinoma, Quinazolines, Organic compounds, Cancer, Branches of biology, Chloroarenes

CLN-081 is an orally available, irreversible EGFR inhibitor, utilizing a unique pyrrolopyrimidine scaffold that was designed to selectively target cells expressing mutant EGFR variants, including exon 20, while sparing cells expressing wild type (WT) EGFR.

Key Points: 
  • CLN-081 is an orally available, irreversible EGFR inhibitor, utilizing a unique pyrrolopyrimidine scaffold that was designed to selectively target cells expressing mutant EGFR variants, including exon 20, while sparing cells expressing wild type (WT) EGFR.
  • The current analysis of the ongoing trial evaluated a total of 45 NSCLC patients with EGFR exon 20 insertion mutations who received at least one dose of CLN-081 as of the April 1, 2021, data cutoff, and were evaluable for safety.
  • As of the data cutoff, 42 of 45 patients were response evaluable across all dose cohorts tested.
  • Cullinan is evaluating various doses of CLN-081 in a Phase 1/2a trial in patients with NSCLC harboring Ins20 mutations that have progressed post chemotherapy.

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

Retrieved on: 
Friday, May 28, 2021
Tyrosine kinase receptors, ROS1, Lung cancer, Non-small-cell lung carcinoma, Health sciences, Health, Clinical endpoint, Medical research

Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China (mainland China, Hong Kong, Macau, and Taiwan).

Key Points: 
  • Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China (mainland China, Hong Kong, Macau, and Taiwan).
  • The registrational Phase 2 portion of TRIDENT-1 study is a multi-center trial evaluating repotrectinib for the treatment of patients with ROS1+ advanced NSCLC as well as patients with NTRK+ advanced solid tumors.
  • The primary endpoint of the Phase 2 portion of the trial is overall response rate (ORR) assessed by Blinded Independent Central Review (BICR).
  • Zai Lab is enrolling patients in Greater China, while Turning Point is enrolling patients in other regions of the world.

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 26, 2021
Enzymes, Tyrosine kinase inhibitors, Chemical compounds, Entospletinib, Indazoles, Morpholines, Tyrosine kinase receptors, Tyrosine kinases, Branches of biology, CD135, Tyrosine-protein kinase SYK, Acute myeloid leukemia

The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .

Key Points: 
  • The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bio is developing a portfolio of spleen tyrosine kinase (SYK) inhibitors, entospletinib (ENTO) and lanraplenib (LANRA), for the treatment of NPM1-mutated and FLT3-mutated acute myeloid leukemia (AML).
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

Arvinas to Present at the UBS Global Healthcare Virtual Conference

Retrieved on: 
Thursday, May 20, 2021
Biotechnology, Life sciences, Tyrosine kinase receptors, Pharmacology, Proteolysis targeting chimera, HER2/neu, Biology, Branches of biology

A replay of the webcast will be archived on Arvinas\xe2\x80\x99 website for 30 days following the presentation.\nArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.

Key Points: 
  • A replay of the webcast will be archived on Arvinas\xe2\x80\x99 website for 30 days following the presentation.\nArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
  • Arvinas uses its proprietary PROTAC\xc2\xae Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC\xc2\xae targeted protein degraders, that are designed to harness the body\xe2\x80\x99s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
  • In addition to its robust preclinical pipeline of PROTAC\xc2\xae protein degraders against validated and \xe2\x80\x9cundruggable\xe2\x80\x9d targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
  • For more information, visit www.arvinas.com .\n'

Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

Retrieved on: 
Wednesday, May 19, 2021
Tyrosine kinase receptors, Branches of biology, Clinical medicine, HER2/neu, Medicine, Epidermal growth factor receptor

These data provide early proof-of-concept for BDTX-189, including evidence of anti-cancer activity and a safety profile that is in-line with the Company\xe2\x80\x99s preclinical expectations.

Key Points: 
  • These data provide early proof-of-concept for BDTX-189, including evidence of anti-cancer activity and a safety profile that is in-line with the Company\xe2\x80\x99s preclinical expectations.
  • The dose-escalation portion successfully enrolled patients with a broad range of tumor types and genomic alterations.
  • These mutations include extracellular domain allosteric mutations of HER2, as well as EGFR and HER2 kinase domain Exon 20 insertions, and additional activating oncogenic drivers of EGFR and HER2.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Long-term Data on Vitrakvi® (larotrectinib) Further Demonstrate Strong Clinical Profile in Patients with TRK Fusion Cancer Regardless of Tumor Type and Age

Retrieved on: 
Wednesday, May 19, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Fitness & Nutrition, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Health sciences, Health, Tyrosine kinase receptors, Orphan drugs, Clinical medicine, Larotrectinib, Cancer, Clinical trial, Trk receptor, Vitrakvi® (larotrectinib), TRK Fusion Cancer, Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), TRK FUSION CANCER, ONCOLOGY AT BAYER, BAYER

In addition, an intra-patient pooled retrospective analysis assessing the treatment effect of Vitrakvi in patients with TRK fusion cancer previously treated with one or more line of therapy were presented.

Key Points: 
  • In addition, an intra-patient pooled retrospective analysis assessing the treatment effect of Vitrakvi in patients with TRK fusion cancer previously treated with one or more line of therapy were presented.
  • Two percent of patients discontinued Vitrakvi due to TRAEs and no treatment-related deaths were reported.\nData for the integrated dataset were pooled from three Vitrakvi clinical trials (NCT02122913, NCT02576431 and NCT02637687) in adult and pediatric patients with TRK fusion cancer.
  • These TRK fusion proteins are oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer.
  • Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer \xe2\x80\x93 an expanded dataset [abstract].

Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC

Retrieved on: 
Wednesday, May 19, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Lung cancer, Cancer treatments, Tyrosine kinase receptors, Cancer, Clinical medicine, Medicine, Treatment of lung cancer, Epidermal growth factor receptor, HER2/neu, Non-small-cell lung carcinoma, Mobocertinib (TAK-788), the Phase 1/2 Trial, EGFR Exon20 Insertion+ mNSCLC, Takeda Pharmaceutical Company Limited, MOBOCERTINIB (TAK-788), THE PHASE 1/2 TRIAL, EGFR EXON20 INSERTION+ MNSCLC, TAKEDA PHARMACEUTICAL COMPANY LIMITED

Additional information, including the specific conditions to qualify for Takeda\xe2\x80\x99s EAP, is available here .\nLearn more about Takeda Oncology\xe2\x80\x99s presence at this year\xe2\x80\x99s ASCO Annual Meeting .

Key Points: 
  • Additional information, including the specific conditions to qualify for Takeda\xe2\x80\x99s EAP, is available here .\nLearn more about Takeda Oncology\xe2\x80\x99s presence at this year\xe2\x80\x99s ASCO Annual Meeting .
  • ET to discuss these and other data being presented at ASCO and to provide an update on the oncology pipeline.
  • In 2019, the U.S. FDA granted mobocertinib Orphan Drug Designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations.
  • In April 2020, mobocertinib received Breakthrough Therapy Designation from the FDA for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after platinum-based chemotherapy.

Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers

Retrieved on: 
Tuesday, May 11, 2021
Tyrosine kinase receptors, ROS1, Anaplastic lymphoma kinase, Targeted therapy, Branches of biology, Protein kinase inhibitor, Kinase, Clinical medicine, Medicine, Entrectinib

b'CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing.

Key Points: 
  • b'CAMBRIDGE, Mass., May 11, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing.
  • "With this financing, we are well positioned to efficiently advance our parallel lead programs into clinical development and to accelerate the discovery of additional novel, selective compounds to meet medical needs in treatment-resistant cancers.
  • "\nProceeds from the Series B financing will support the clinical advancement of Nuvalent\'s parallel lead programs, NVL-520 (previously NUV-520), a potential best-in-class ROS1-selective kinase inhibitor, and NVL-655 (previously NUV-655), a potential best-in-class ALK-selective kinase inhibitor.
  • "\nNuvalent, Inc. is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer.